|
Jul 31
|
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
|
|
Jul 29
|
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
|
|
Jul 28
|
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
|
|
Jul 2
|
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
|
|
May 8
|
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
|
|
Jun 3
|
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
|
|
May 20
|
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
|
|
May 16
|
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Mar 28
|
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
|
|
Mar 26
|
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
|
|
Mar 25
|
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
|